Ablation Equipments - Medical Devices Pipeline Assessment, 2018

Ablation Equipments - Medical Devices Pipeline Assessment, 2018


  • Products Id :- GDME0690EPD
  • |
  • Pages: 143
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Ablation Equipments-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Ablation Equipments-Medical Devices Pipeline Assessment, 2018" provides an overview of Ablation Equipments currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ablation Equipments pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Ablation Equipments under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Ablation Equipments under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 9

2.1 Ablation Equipments Overview 9

3 Products under Development 10

3.1 Ablation Equipments-Pipeline Products by Stage of Development 10

3.2 Ablation Equipments-Pipeline Products by Territory 11

3.3 Ablation Equipments-Pipeline Products by Regulatory Path 12

3.4 Ablation Equipments-Pipeline Products by Estimated Approval Date 13

3.5 Ablation Equipments-Ongoing Clinical Trials 14

4 Ablation Equipments-Pipeline Products under Development by Companies 15

4.1 Ablation Equipments Companies-Pipeline Products by Stage of Development 15

4.2 Ablation Equipments-Pipeline Products by Stage of Development 16

5 Ablation Equipments Companies and Product Overview 17

5.1 AngioDynamics Inc Company Overview 17

5.1.1 AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 17

5.2 Avenda Health Inc Company Overview 32

5.2.1 Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.3 CPSI Biotech Company Overview 33

5.3.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 33

5.4 Creo Medical Ltd. Company Overview 35

5.4.1 Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 35

5.5 Deneb Medical SL Company Overview 36

5.5.1 Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview 36

5.6 Fractyl Laboratories Inc Company Overview 37

5.6.1 Fractyl Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 37

5.7 Harmonic Medical Inc Company Overview 41

5.7.1 Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.8 HistoSonics Inc Company Overview 44

5.8.1 HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview 44

5.9 Hospital for Special Surgery Company Overview 45

5.9.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 45

5.10 Imricor Medical Systems Inc Company Overview 46

5.10.1 Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 46

5.11 Innoblative Designs, Inc. Company Overview 49

5.11.1 Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49

5.12 Integra LifeSciences Holdings Corp Company Overview 50

5.12.1 Integra LifeSciences Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview 50

5.13 Intratherm LLC (Inactive) Company Overview 52

5.13.1 Intratherm LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52

5.14 Massachusetts Institute of Technology Company Overview 53

5.14.1 Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 53

5.15 Medtronic plc Company Overview 54

5.15.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 54

5.16 Memorial Sloan Kettering Cancer Center Company Overview 56

5.16.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 56

5.17 Mirabilis Medical Inc Company Overview 57

5.17.1 Mirabilis Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 57

5.18 Pulse Biosciences Inc Company Overview 60

5.18.1 Pulse Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.19 Southern Illinois University Carbondale Company Overview 61

5.19.1 Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview 61

5.20 Thermedical Inc Company Overview 62

5.20.1 Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview 62

5.21 TransEnterix Inc Company Overview 63

5.21.1 TransEnterix Inc Pipeline Products & Ongoing Clinical Trials Overview 63

5.22 University of California San Francisco Company Overview 64

5.22.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 64

5.23 University of Texas at Austin Company Overview 65

5.23.1 University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview 65

5.24 University of Wisconsin-Stout Company Overview 66

5.24.1 University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview 66

6 Ablation Equipments- Recent Developments 67

6.1 Jul 11, 2018: AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results 67

6.2 Jul 10, 2018: Stryker announces organizational changes 68

6.3 Jul 05, 2018: SonaCare reports long-term results of HIFU therapy for prostate cancer 69

6.4 Jun 23, 2018: Fractyl Announces Presentation of Key Scientific Research at ADA 2018 Indicating That Modern Diets Durably Alter Duodenal Lining, Highlighting the Intestine's Role in Type 2 Diabetes and NASH 69

6.5 Jun 14, 2018: HSS Hip and Knee Surgeon Bradford Waddell, MD, Named Chair of Young Arthroplasty Group 71

6.6 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 71

7 Appendix 139

7.1 Methodology 139

7.2 About GlobalData 142

7.3 Contact Us 142

7.4 Disclaimer 142

1.2 List of Figures

Figure 1: Ablation Equipments-Pipeline Products by Stage of Development 11

Figure 2: Ablation Equipments-Pipeline Products by Territory 12

Figure 3: Ablation Equipments-Pipeline Products by Regulatory Path 13

Figure 4: Ablation Equipments-Pipeline Products by Estimated Approval Date 14

Figure 5: Ablation Equipments-Ongoing Clinical Trials 15

1.1 List of Tables

Table 1: Ablation Equipments-Pipeline Products by Stage of Development 11

Table 2: Ablation Equipments-Pipeline Products by Territory 12

Table 3: Ablation Equipments-Pipeline Products by Regulatory Path 13

Table 4: Ablation Equipments-Pipeline Products by Estimated Approval Date 14

Table 5: Ablation Equipments-Ongoing Clinical Trials 15

Table 6: Ablation Equipments Companies-Pipeline Products by Stage of Development 16

Table 7: Ablation Equipments-Pipeline Products by Stage of Development 17

Table 8: AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview 18

Table 9: NanoKnife 3.0-Product Status 18

Table 10: NanoKnife 3.0-Product Description 19

Table 11: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-Product Status 19

Table 12: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-Product Description 19

Table 13: NanoKnife System-Pancreatic Cancer-Product Status 20

Table 14: NanoKnife System-Pancreatic Cancer-Product Description 20

Table 15: NanoKnife System-Prostate Cancer-Product Status 20

Table 16: NanoKnife System-Prostate Cancer-Product Description 21

Table 17: AngioDynamics Inc-Ongoing Clinical Trials Overview 22

Table 18: NanoKnife System-Prostate Cancer-Efficacy and Safety Assessment of Nanoknife (AngyoDynamics, USA) for Irreversible Electroporation (IRE) of Localized Prostate Cancer 24

Table 19: NanoKnife System-Prostate Cancer-Focal Irreversible Electroporation as Salvage Treatment in Radio-recurrent Prostate Cancer: A Prospective Multicenter Pilot Study 24

Table 20: NanoKnife System-Prostate Cancer-Irreversible Electroporation (IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial 24

Table 21: NanoKnife System-Prostate Cancer-Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer 25

Table 22: NanoKnife System-Prostate Cancer-Registry of Irreversible Electroporation for the Ablation of Prostate Cancer with Use of Nanoknife Device; A Multi-center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety 25

Table 23: NanoKnife System-Pancreatic Cancer-A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer 26

Table 24: NanoKnife System-Pancreatic Cancer-A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas 26

Table 25: NanoKnife System-Pancreatic Cancer-Assessing Optimal Treatment Settings for the Ablation of Locally Advanced Pancreatic Cancer with CT-guided Percutaneous Irreversible Electroporation (ANTILOPE): A Randomized Feasibility Study 26

Table 26: NanoKnife System-Pancreatic Cancer-Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival after Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation: CROSSFIRE Trial 27

Table 27: NanoKnife System-Pancreatic Cancer-Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System-A Prospective Study 27

Table 28: NanoKnife System-Pancreatic Cancer-Impact of Irreversible Electroporation on Quality of Life for Patients with Locally Advanced Pancreatic Cancer 27

Table 29: NanoKnife System-Pancreatic Cancer-Interest of Irreversible Electroporation in the Treatment of Pancreatic Adenocarcinoma 28

Table 30: NanoKnife System-Pancreatic Cancer-IRE: Anti-tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer 28

Table 31: NanoKnife System-Pancreatic Cancer-Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial 28

Table 32: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder 29

Table 33: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers 29

Table 34: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE)-A Phase II Clinical Trial: COLDFIRE-2 Study 29

Table 35: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer 30

Table 36: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome 30

Table 37: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE) 30

Table 38: NanoKnife Low Energy Direct Current System-Hepatocellular Carcinoma-Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial 31

Table 39: NanoKnife 3.0-The Safety and Feasibility of Irreversible Electroporation for the Ablation of Small Renal Masses 32

Table 40: Avenda Health Inc Pipeline Products & Ongoing Clinical Trials Overview 33

Table 41: Fiber-Optic Laser-Product Status 33

Table 42: Fiber-Optic Laser-Product Description 33

Table 43: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 34

Table 44: Pressurized Sub-Cooled Nitrogen System-Product Status 34

Table 45: Pressurized Sub-Cooled Nitrogen System-Product Description 34

Table 46: Super-Critical Nitrogen (SCN) Cryoablation Platform-Product Status 34

Table 47: Super-Critical Nitrogen (SCN) Cryoablation Platform-Product Description 35

Table 48: Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview 36

Table 49: Flexible Ablation System-Product Status 36

Table 50: Flexible Ablation System-Product Description 36

Table 51: Deneb Medical SL Pipeline Products & Ongoing Clinical Trials Overview 37

Table 52: BoneCut Collaborative Robot-Product Status 37

Table 53: BoneCut Collaborative Robot-Product Description 37

Table 54: Fractyl Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 38

Table 55: Revita DMR System-Product Status 38

Table 56: Revita DMR System-Product Description 38

Table 57: Fractyl Laboratories Inc-Ongoing Clinical Trials Overview 39

Table 58: Revita DMR System-Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study 40

Table 59: Revita DMR System-Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes 40

Table 60: Revita DMR System-Evaluation of the Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D) 40

Table 61: Revita DMR System-Multicenter Clinical Trial of Revita DMR Procedure in Patients with Diabetes 41

Table 62: Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 42

Table 63: Symphony MRI guided High Intensity Focused Ultrasound-Leiomyomas-Product Status 42

Table 64: Symphony MRI guided High Intensity Focused Ultrasound-Leiomyomas-Product Description 42

Table 65: Harmonic Medical Inc-Ongoing Clinical Trials Overview 43

Table 66: Symphony MRI guided High Intensity Focused Ultrasound-Leiomyomas-MRI-guided High Intensity Focused Ultrasound Ablation of Leiomyomas. Single Arm, Feasibility Study Using the Symphony-MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas. 44

Table 67: HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview 45

Table 68: Vortx RX-Product Status 45

Table 69: Vortx RX-Product Description 45

Table 70: Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 46

Table 71: Radiofrequency Ablation Device-Product Status 46

Table 72: Radiofrequency Ablation Device-Product Description 46

Table 73: Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 47

Table 74: Vision MR Ablation Catheter-Product Status 47

Table 75: Vision MR Ablation Catheter-Product Description 47

Table 76: Imricor Medical Systems Inc-Ongoing Clinical Trials Overview 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AngioDynamics Inc

Avenda Health Inc

CPSI Biotech

Creo Medical Ltd.

Deneb Medical SL

Fractyl Laboratories Inc

Harmonic Medical Inc

HistoSonics Inc

Hospital for Special Surgery

Imricor Medical Systems Inc

Innoblative Designs, Inc.

Integra LifeSciences Holdings Corp

Intratherm LLC

Massachusetts Institute of Technology

Medtronic plc

Memorial Sloan Kettering Cancer Center

Mirabilis Medical Inc

Pulse Biosciences Inc

Southern Illinois University Carbondale

Thermedical Inc

TransEnterix Inc

University of California San Francisco

University of Texas at Austin

University of Wisconsin-Stout

AngioDynamics Inc, NanoKnife 3.0; AngioDynamics Inc, NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma; AngioDynamics Inc, NanoKnife System - Pancreatic Cancer; AngioDynamics Inc, NanoKnife System - Prostate Cancer; Avenda Health Inc, Fiber - Optic Laser; CPSI Biotech, Pressurized Sub-Cooled Nitrogen System; CPSI Biotech, Super-Critical Nitrogen (SCN) Cryoablation Platform; Creo Medical Ltd., Flexible Ablation System; Deneb Medical SL, BoneCut Collaborative Robot; Fractyl Laboratories Inc, Revita DMR System; Harmonic Medical Inc, Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas; HistoSonics Inc, Vortx RX; Hospital for Special Surgery, Radiofrequency Ablation Device; Imricor Medical Systems Inc, Vision MR Ablation Catheter; Innoblative Designs, Inc., RFA Applicator; Integra LifeSciences Holdings Corp, CUSA Accessories; Integra LifeSciences Holdings Corp, CUSA Ultrasonic Tissue Ablation System - Liver; Intratherm LLC (Inactive), CITT Device; Massachusetts Institute of Technology, Image Guided Endoscopic Ablation Device; Medtronic plc, Barrx 360 Express RFA Balloon Catheter; Medtronic plc, Nerve Cryoablation System; Memorial Sloan Kettering Cancer Center, Image-Guided Ablation Device; Mirabilis Medical Inc, Mirabilis System; Pulse Biosciences Inc, PulseTx System - Soft Tissue Ablation; Southern Illinois University Carbondale, Thermoablation Probe; Thermedical Inc, SERF Ablation System - Fibroids; TransEnterix Inc, Barrett's Excision Device; University of California San Francisco, Robotic Needle Ablation Tool And Securement Device; University of Texas at Austin, Plasmonic Laser Ablation Device; University of Wisconsin-Stout, Microwave Ablation Probe

select a license
Single User License
USD 4000 INR 285560
Site License
USD 8000 INR 571120
Corporate User License
USD 12000 INR 856680

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com